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Introduction
Despite advances in pharmacotherapeutic strategies, congestive 
heart failure (HF) is a chronic disease and a major public health con-
cern because of its high morbidity and mortality.1) In advanced HF 
with severe systolic dysfunction {left ventricular ejection fraction 
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(LVEF) ≤35%} with wide QRS interval (>120 ms), device therapies 
such as cardiac resynchronization therapy (CRT) have been shown 
to improve prognosis.2-4)
Evidence from several studies revealed that CRT significantly re-
duces mortality and all-cause hospitalizations in patients with ad-
vanced HF.5)6) The Comparison of Medical Therapy, Pacing, and Defi-
brillation in Heart Failure study demonstrated that use of CRT was 
associated with a significant 20% decrease in mortality of advanc-
ed HF at 6 month follow-up.5-8) The Cardiac Resynchronization-He-
art Failure trial showed a significant 36% decrease in the combined 
end point of all-cause mortality and HF hospitalizations with CRT.5)6) 
Recent studies revealed that CRT is still underutilized in clinical 
practice with significant variations despite being recommended.9) 
To facilitate the consideration of CRT, we investigated prognostic 
factors in patients with advanced HF who were suitable candidates 
for CRT but were treated by conventional strategy. In addition, we 
developed a risk model to identify the patients who had poor prog-
nosis. The validity of this model was tested in a separate group of 
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patients. 
 
Subjects and Methods
 
Study population 
Between January 2007 and February 2009, 1345 patients with HF 
visited the tertiary referral hospital (Severance Cardiovascular Hos-
pital, South Korea). Of these, 239 patients (18%) who had advanced 
HF {New York Heart Association (NYHA) functional class II-IV and 
LVEF ≤35%} with a wide QRS interval (>120 ms) were consecu-
tively enrolled. Patients 1) who received device therapy or heart tr-
ansplantation and 2) who had a malignancy were excluded from 
this study (Fig. 1). For the validation of a risk model, 66 patients were 
enrolled from a different affiliated institution (Kangnam Severance 
Hospital, South Korea) with the same inclusion and exclusion criteria 
(validation cohort) during the same period. 
 
Echocardiography and electrocardiogram measurements
Echocardiography was performed on all patients at the index vis-
it. A standard echocardiography was performed and the left ventric-
ular end diastolic diameter (LVEDD), left arterial volume index, and 
early mitral inflow velocity to early diastolic mitral annular velocity 
(E/E’) were measured. LVEF was measured by the Simpson method. 
All electrocardiograms were recorded at a 25 mm/s sweep speed, 
and QRS duration was measured by 2 experienced cardiologists 
from lead V2.
 
Clinical and biochemical data
Demographic variables, co-morbidities, and medications were 
collected at the index visit. Biochemical data included the following 
variables: serum hemoglobin (Hb), hematocrit (Hct), creatinine (SCr), 
sodium (Na), and total cholesterol. The rhythm and QRS interval on 
ECG were also obtained and analyzed.
 
Outcomes
In order to identify and evaluate risk factors associated with prog-
nosis in advanced HF, we retrospectively reviewed the clinical course. 
The primary end point of the study was all-cause death during the 
follow-up period. We also investigated a composite endpoint of 
all-cause death and unplanned hospitalization due to major adverse 
cardiovascular event (MACE; worsening HF, acute coronary syn-
drome, and fatal arrhythmia). 
  
Statistical analysis 
Continuous variables were expressed as the mean and standard 
deviations. Baseline characteristics were compared by chi-square 
analysis for dichotomous variables and Student’s t-test for contin-
uous variables. Cox proportional hazard regression analysis was per-
formed to evaluate the relationship between risk factors and out-
comes. To develop a prognostic model, we assigned the risk factors 
identified by multivariate analysis weighted points based on β re-
gression coefficient values. Survival curves were constructed ac-
cording to the Kaplan-Meier method and comparisons of the sur-
vival rate between risk groups were compared using the log-rank 
test. The discriminative ability of our prediction model was evalu-
ated by receiver-operating curve analysis (C statistic). P were all 2- 
sided and considered to be statistically significant at p<0.05. SAS 
(version 9.1.3, SAS Institute Inc., Cary, NC, USA) was used for all statis-
tical analysis. 
 
Results
 
Patient characteristics
The clinical characteristics and the use of various cardiac medic-
ations at the time of enrollment are presented in Table 1. Our sub-
ject group consisted of 239 patients (160 males) with a mean age of 
67±11 years. The mean duration of the follow-up was 308±236 
days. From this group, 56 (23%) patients died. The etiology of HF in-
cluded 131 (55%) ischemic cases and 108 (45%) non-ischemic cases. 
There were 131 (55%) hypertensive and 94 (39%) diabetic patients, 
and 141 (59%) were chronic kidney disease (CKD) patients. 77 (32%) 
patients suffered from atrial fibrillation. 
The mean LVEF was 25±7% and the mean QRS interval was 145± 
20 ms. All patients were being treated with diuretics (68%), aldo-
sterone receptor blockers (39%), angiotensin converting enzyme in-
hibitors (10%), angiotensin II receptor blockers (32%), and digoxin 
(27%). Beta-blockers were taken by only 12 (5%) patients. 
 
All-cause death
By the end of the study, all-cause death (primary end point) oc-
curred in 56 (23%) patients. Table 2 presents the univariate analy-
sis that identified risk factors affecting all-cause death. The follow-
ing demographic, clinical, biochemical, and echocardiography vari-
Congestive heart failure
(n=1345) Exclusions
NYHA class I (n=751)
LVEF >35% (n=83)
QRS <120 ms (n=244)
Pacemaker or ICD (n=28)Eligible patient
(LVEF ≤35%, QRS ≥120 ms) (n=239)
Survivor (n=183) (77%) Non-survivor (n=56) (23%)
Fig. 1. Diagram of study workflow. CHF: congestive heart failure, LVEF: left 
ventricular ejection fraction, ICD: implantable cardioverter-defibrillator.
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Table 1. Baseline demographic and clinical characteristics in the derivation cohort
Variables Non-survivor (n=56) Survivor (n=183)  p
Age (years) 70±13 66±11 0.046
Male, n (%) 35 (63) 125 (68) 0.419
Etiology of heart failure, n (%)
Ischemic 32 (57) 99 (54) 0.689
Non-ischemic 24 (43) 84 (46)
NYHA class, n (%) <0.001
II 6 (11) 69 (38)
III 16 (29) 72 (39)
IV 34 (61) 42 (23)
Co-morbidity, n (%)
Hypertension 37 (66) 94 (51) 0.053
Diabetes mellitus 25 (45) 69 (38) 0.352
Chronic kidney disease 40 (71) 101 (55) 0.031
Dyslipidemia 86 (47) 23 (41) 0.436
Body mass index ≥25 (kg/m2) 9 (16) 55 (30) 0.049
Prior stroke 8 (14) 10 (5.5) 0.092
Smoking 13 (23) 57 (31) 0.069
Thyroid disease 6 (11) 14 (7.7) 0.749
Clinical and Laboratory findings at enrollment
Systolic BP (mm Hg) 115±22 113±14 0.773
Diastolic BP (mm Hg) 96±12 105±10 0.003
Heart rate (bpm) 90±20 78±15 <0.001
Hb (g/dL) 11±2 13±2 <0.001
Creatinine (mg/dL) 2.7±2.4 1.6±1.7 0.003
Total cholesterol (mg/dL) 125±49 155±45 <0.001
NT-proBNP (pg/mL) 23282±51786 9281±10885 0.01
Echocardiographic findings 
LVEF (%) 22±7 26±7 <0.001
LVEDD (mm) 61±12 64±9 0.015
LA volume index (mm3/m2) 50±30 50±31 0.998
E/E’ 22±10 24±12 0.509
EKG findings
Atrial fibrillation, n (%) 20 (36) 57 (31) 0.626
QRS duration (ms) 142±20 146±21 0.147
Medications, n (%)  
Aldosterone antagonists 23 (41) 70 (38) 0.705
ACE inhibitors 22 (39) 70 (38) 0.472
Angiotensin receptor blockers 10 (18) 67 (37) 0.009
Beta blockers 16 (29) 107 (58) <0.001
Digitalis 13 (23) 51 (28) 0.491
Diuretics 35 (63) 127 (69) 0.334
Data are expressed as n (%) or mean±standard deviation. NYHA: New York Heart Association, BP: blood pressure, Hb: hemoglobin, NT-proBNP: N-terminal pro-
B-type natriuretic peptide, LVEF: left ventricular ejection fraction, LVEDD: left ventricular end diastolic diameter, LA: left atrium, EKG: electrocardiography, ACE: 
angiotensin converting enzyme
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ables had significant correlations with all-cause death: NYHA class 
(III, IV vs. II) {hazard ratio (HR) 4.2; 95% confidence interval (CI): 1.81 
to 9.87; p<0.001}, body mass index (≥25 kg/m2) (1.7; 95% CI: 1.01 
to 3.04; p=0.05), the presence of hypertension (0.5; 95% CI: 0.23 
to 0.98; p=0.04), CKD (2.1; 95% CI: 1.17 to 3.75; p=0.01), prior stroke 
(2.1; 95% CI: 1.00 to 4.47; p=0.05), LVEF (≤25%) (2.7; 95% CI: 1.55 
to 4.68; p<0.001), LVEDD (≥55 mm) (0.4; 95% CI: 0.21 to 0.65; p< 
0.001), heart rate (>90 bpm) (6.3; 95% CI: 3.7 to 10.6; p<0.001), se-
rum Hb (2.7; 95% CI: 1.30 to 4.14; p<0.001), serum Na (≤135 mEq/L) 
(2.74; 95% CI: 1.62 to 4.63; p<0.001), and serum creatinine (≥1.5 
mg/dL) (3.3; 95% CI: 1.96 to 5.69; p<0.001).
Next, we analyzed significant factors by stepwise multivariate 
analysis. Prior stroke (HR 2.7; 95% CI: 1.23 to 6.13; p=0.01), heart 
rate (>90 bpm) (4.6; 95% CI: 2.51 to 8.59; p<0.001), serum Na 
(≤135 mEq/L) (2.9; 95% CI: 1.61 to 5.37; p<0.001), and serum creati-
nine (≥1.5 mg/dL) (1.9; 95% CI: 1.02 to 3.64; p=0.04) were defined 
Table 2. Univariate Cox regression for all-cause mortality
Variables Regression coefficient Hazard ratio 95% CI p
Age 0.016 1.023 0.998-1.049 0.070 
Male 0.082 0.790 0.460-1.357 0.393 
IHD -0.294 1.180 0.695-2.004 0.541 
NYHA class III, IV 0.702 4.231 1.814-9.870 <0.001
BMI ≥25 (kg/m2) -0.235 1.749 1.005-3.044 0.048
HTN -0.204 0.474 0.230-0.977 0.043
DM -0.001 1.331 0.785-2.257 0.289 
CKD 0.131 2.093 1.169-3.748 0.013
Prior stroke 1.527 2.114 0.999-4.471 0.050
Thyroid disease -0.001 0.739 0.316-1.727 0.485 
Atrial fibrillation 0.065 1.164 0.674-2.012 0.586 
QRS duration -0.005 0.990 0.976-1.004 0.160 
Smoking -0.067 1.743 0.937-3.242 0.080 
LVEF ≤25 (%) 0.999 2.693 1.548-4.683 <0.001
LVEDD ≥55 (mm) -1.285 0.371 0.213-0.646 <0.001
Heart rate >90 (bpm) 1.311 6.269 3.691-10.647 <0.001
Hb ≤12 (g/dL) 0.605 2.316 1.296-4.139 0.005
Na ≤135 (mEq/L) 1.098 2.735 1.615-4.631 <0.001
Scr ≥1.5 (mg/dL) 0.514 3.339 1.959-5.689 <0.001
Aldosterone antagonists 0.064 1.066 0.626-1.816 0.814
ACE inhibitors -0.287 0.751 0.271-2.076 0.580
Angiotensin receptor blockers -0.957 0.384 0.194-0.762 0.006
Beta blockers -1.225 0.294 0.041-2.124 0.225
Digitalis -0.301 0.740 0.398-1.377 0.342
Diuretics -0.286 0.751 0.437-1.291 0.301
CI: confidence interval, IHD: ischemic heart disease, NYHA: New York Heart Association, BMI: body mass index, HTN: hypertension, DM: diabetes mellitus, 
CKD: chronic kidney disease, LVEF: left ventricular ejection fraction, LVEDD: left ventricular end diastolic diameter, Hb: hemoglobin, Na: sodium, Scr: serum 
creatinine, ACE: angiotensin converting enzyme
Table 3. Multivariate Cox regression analysis for all-cause death and risk score
Regression coefficient Hazard ratio 95% CI p Points*
Prior stroke 1.01 2.746 1.231-6.126 0.014 3
Heart rate >90 (bpm) 1.54 4.646 2.512-8.591 <0.001 5
Na ≤135 (mEq/L) 1.08 2.941 1.612-5.365 <0.001 3
Scr ≥1.5 (mg/dL) 0.65 1.924 1.016-3.643 0.045 2
*Assignment of points was based on a linear transformation of the corresponding β regression coefficient. The coefficient of each variable was divided by 
0.65 (the lowest β value), multiplied by a constant (2), and rounded to the nearest integer.10)  CI: confidence interval, Scr: serum creatinine
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as significant predictors (Table 3).
All-cause death or unplanned hospitalization for a major 
cardiovascular event
The secondary end point (all-cause death or unplanned hospita-
lization due to MACE) occurred in 92 (38%) patients (Fig. 2). In mul-
tivariate analysis, NYHA class (III, IV vs. II) (2.0; 95% CI: 1.05 to 3.71; 
p=0.04), heart rate (>90 bpm) (2.16; 95% CI: 1.29 to 3.62; p=0.01), 
serum Na (<135 mEq/L) (2.53; 95% CI: 1.59 to 4.03; p<0.001), and 
serum creatinine (≥1.5 mg/dL) (2.1; 95% CI: 1.20 to 3.58; p=0.01) 
were identified as significant risk factors. 
 
Prognostic modeling and risk stratification
We assigned scores to risk factors based on a linear transforma-
tion of the corresponding β regression coefficients, as previously 
described in Anis Rassi’s article.10) The coefficient of each variable 
was divided by the lowest β value, then multiplied by a constant (2), 
and rounded to the nearest integer (Table 3). 
The risk model calculated a score by adding together the points 
corresponding to patient’s risk factors: {Risk score=3×prior st-
roke+5×heart rate (>90 bpm)+3×serum Na (≤135 mEq/L)+2×serum 
creatinine (≥1.5 mg/dL)}. 
All patients were stratified into three groups based on risk score. 
The cut-points were obtained by maximizing the c-index: low-(0 
point), intermediate- (1-5 points), and high-risk group (>5 points). 
There were 119 (50%) patients identified as low, 81 (34%) patients 
as intermediate and 39 patients identified (16%) as high-risk group.
The 2-year mortality rates of each group were 5% (6/119), 31% 
(25/81), and 64% (25/39), respectively. Compared with the low-risk 
group, the HR of the high-risk group was 20.9 (95% CI: 8.6 to 51.3; 
p<0.001) and intermediate-risk group was 6.7 (95% CI: 2.7 to 16.3; 
p<0.001). The C statistic for the risk model for prediction of mortali-
ty was 0.78 (Fig. 3A, Table 4).
 
Atrial fibrillation and mortality
Although CRT in advanced HF with atrial fibrillation was not a 
class I indication,2) many studies have reported the benefits of CRT 
to advanced HF with atrial fibrillation.11) In our study, 77 patients had 
atrial fibrillation and 20 (26%) patients had died. We re-classified 
patients based on the risk score. In these patients, the high-risk gr-
oup with atrial fibrillation showed higher mortality risk than the 
low-risk group (HR 32.1; 95% CI: 4.1-251.4; p=0.001). 
Validation of the prediction model
A total of 66 patients from a different hospital were selected as the 
validation cohort (Table 1 and 5). During a mean follow-up of 686± 
367 days, 13 patients (20%) died. Classification of the validation co-
Fig. 2. Primary outcome: all-cause death. Secondary outcome: the com-
posite of all-cause death or unplanned hospitalization due to major ad-
verse cardiovascular event.
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hort according to their risk score resulted in the assignment of 36 
patients (55%) to the low-, 20 patients (30%) to the intermediate- 
and 10 patients (15%) to the high-risk groups. The 2-year mortality 
rates for these three groups were 3% (1/36), 30% (6/20), and 50% 
(5/10), respectively. The C statistic was 0.80. Compared with the low-
risk group, the HR of the high-risk group was 12.9 (95% CI: 2.5 to 
67.4; p=0.002) and intermediate-risk group was 6.2 (95% CI: 1.2 to 
30.6; p=0.026) (Fig. 3B, Table 5). 
 
Discussion
Our study demonstrated that patients with advanced HF who 
were suitable for CRT but treated with a conventional strategy ex-
hibited high mortality (56 deaths, 23%) by the time of the follow-
up examinations. The risk of death in advanced HF is predicted by 
the presence of 4 independent risk factors, which are prior stroke, 
heart rate (>90 bpm), serum Na (≤135 mEq/L), and serum creatinine 
(>1.5 mg/dL). We developed a risk model using these factors and st-
ratified patients into the low-, intermediate-, and high-risk groups 
according to their risk score. The high-risk group demonstrated a 
21-fold higher mortality risk compared to the low-risk group. This 
risk model was also validated in terms of risk stratification and mor-
tality prediction. 
Cardiac resynchronization therapy is a well-proven invasive de-
vice therapy in patients with advanced HF. It has been reported to 
improve ventricular conduction delay and ventricular function, re-
duce the magnitude of mitral regurgitation, and increase pulse pres-
sure, cardiac index, as well as reverse remodeling of the ventricle.12) 
However, recent studies revealed that CRT is underutilized in clinical 
practice with significant variations associated with age, insurance, 
QRS interval, and geographic location of practices.9)13) An analysis 
from the Registry to Improve the Use of Evidence-Based Heart Fail-
ure Therapies in the Outpatient Setting found that only 38.8% of 
patients who fit the guidelines for receiving CRT were implanted with 
a CRT device from May 2007 through June 2009 in the United Sta-
tes.13) Based on the European Medical Device Trade Organization re-
gistry, the number of CRT implantations markedly increased from 46/ 
million in 2004 to 99/million in 2008. However, this rate (99/million) 
still indicated only 7% of all eligible HF patients received a CRT device.14)
To facilitate the use of CRT in eligible HF patients, effective risk 
stratification of advanced HF is crucial. Using our model, the high-
risk group showed a markedly grave prognosis compared with the 
low-risk group (2-year mortality 64% vs. 5%, HR 20.9; 95% CI: 8.6 
to 51.3; p<0.001). 
Our prediction model is comprised of 4 independent risk vari-
ables. Stroke was proposed as an independent risk factor associat-
ed with poor prognosis in HF. This is because stroke is an indicator 
of severe LV dysfunction15) and shares common risk factors as well 
as pathophysiological mechanisms with coronary artery disease, 
which is the most common cause of HF.16)17) In the Enhanced Feed-
back for Effective Cardiac Treatment study, a stroke increased 30-
day mortality (odds ratio 1.43; 95% CI: 1.22 to 2.27; p=0.03) am-
ong patients hospitalized for HF.8)
Tachycardia may be a sign of HF and play a role in the deteriora-
tion of cardiac pump function. Several types of tachycardia have 
been related to the development of HF, including atrial fibrillation/
flutter, atrial tachycardia, atrioventricular nodal reentry tachycar-
dia, and ventricular tachycardia.18)
Hyponatremia may also play a role in poor outcomes. This prob-
lem is largely related to the associated fall in cardiac output and 
systemic blood pressure. Patients with hyponatremia showed sig-
nificantly increased mortality compared with normonatremic pa-
tients.19)
Many studies have reported that renal insufficiency is associated 
with adverse cardiovascular outcomes.20)21) McAlister et al.20) have 
shown that HF patients with renal insufficiency exhibited a 1% in-
crease in mortality for each 1 mL/min decrease in creatinine clear-
ance.20)
In our study, prolongation of the QRS interval and enlarged LVEDD 
were not independent predictors for mortality. There was no sig-
nificant difference in QRS interval between the survivor and non-
survivor groups. This finding is in disagreement with previous stud-
ies concerning the prognosis of HF, in which the prolongation of the 
QRS interval was generally associated with poor prognosis in HF.22) 
Table 4. 2-year mortality
Risk category No. (%)
Derivation cohort (n=239)
No. (%)
Validation cohort (n=66)
Death at 2 years (%) Death at 2 years (%)
Low 119 (49.8) 6 (5.0) 36 (54.5) 1 (2.8)
Intermediate 81 (33.9) 25 (30.8) 20 (30.3) 6 (30.0)
High 39 (16.3) 25 (64.1) 10 (15.2) 5 (50.0)
Difference in probability of death* 0.59 0.47
C-statistic 0.78 0.80
The risk category was classified by the mortality prediction model. The prognostic index was categorized into three groups: low-risk (0 point), intermediate-
risk (1 to 5 points), and high-risk (6 to 13 points). *The difference in probability of death was calculated by the formula (Phigh-Plow)/100
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This discrepancy is possibly due to the prolonged QRS interval (>120 
ms) in all enrolled patients.
Left ventricular end diastolic diameter is a known risk factor in the 
prognosis of patients with systolic dysfunction and HF.23) In our 
study, LVEDD was associated with lower odds of all-cause mortality 
based on univariate analysis. This disagreement with previous stud-
ies may be attributed to the enlarged (>55 mm) status of LVEDD in 
most of the enrolled patients. Even though mean LVEDD of survivor 
was slightly larger than the non-survivor, the proportion of patients 
with severe LV dilatation (LVEDD ≥75 mm) was higher in the non-sur-
vivor group (16.1% vs. 13.1%). 
Regarding survival in severe HF, we already have several models 
for evaluation. The Seattle Heart Failure model suggests a 3-year 
survival rate in HF and the Evaluation Study of Congestive Heart 
Failure and Pulmonary Artery Catheterization Effectiveness risk mod-
el predicts 6 month mortality for acute decompensated HF pa-
Table 5. Baseline demographic and clinical characteristics in the derivation cohort and validation cohort
Variables Derivation cohort (n=239) Validation cohort (n=66)  p
Age (years) 67±12 66±11 0.553
Male, n (%) 160 (67) 46 (70) 0.673
NYHA class 0.155
II 75 (31) 29 (44)
III 88 (37) 21 (32)
IV 76 (32) 16 (24)
Co-morbidity, n (%)
Hypertension 131 (55) 37 (56) 0.857
Diabetes mellitus 94 (39) 21 (32) 0.265
Chronic kidney disease 141 (59) 13 (20) <0.001
Body mass index ≥25 (kg/m2) 64 (29) 24 (37) 0.256
Prior stroke 18 (8) 8 (12) 0.237
Smoking 70 (29) 26 (39) 0.341
Thyroid disease 20 (8) 0 (0) 0.015
Clinical and Laboratory findings at enrollment
Systolic BP (mm Hg) 116±17 115±17 0.694
Diastolic BP (mm Hg) 71±11 70±11 0.623
Heart rate (bpm) 81±18 80±20 0.570
Hb (g/dL) 12.1±2.6 13.0±2.3 0.011
Creatinine (mg/dL) 1.9±1.9 1.4±1.1 0.037
Total cholesterol (mg/dL) 147±46 155±45 0.020
Echocardiographic findings 
LVEF (%) 25±7 26±8 0.612
LVEDD (mm) 63±10 60±9 0.005
LA volume index (mm3/m2) 50±30 42±20 0.061
EKG findings
Atrial fibrillation, n (%) 77 (33) 17 (26) 0.260
QRS duration (ms) 145±21 136±23 <0.001
Medications, n (%)  
Aldosterone antagonists 93 (39) 36 (55) 0.023
ACE inhibitors 92 (38) 39 (59) 0.003
Angiotensin receptor blockers 77 (32) 23 (35) 0.687
Beta blockers 123 (51) 42 (64) 0.079
Digitalis 64 (27) 36 (55) 0.004
Diuretics 156 (65) 49 (70) 0.226
Data are expressed as n (%) or mean±standard deviation. NYHA: New York Heart Association, BP: blood pressure, Hb: hemoglobin, LVEF: left ventricular ejec-
tion fraction, LVEDD: left ventricular end diastolic diameter, LA: left atrium, EKG: electrocardiography, ACE: angiotensin converting enzyme
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tients.24)25) 
These two prediction models are more accurate predictors of sur-
vival of advanced HF patients than our prediction model. However, 
these scoring models require more than 10 variables and invasive 
procedures like pulmonary catheterization for accurate prediction. 
In contrast, our prediction model consists of only four risk factors 
and does not require any invasive procedure. 
Our study has several limitations. First, we did not exclude atrial 
fibrillation patients. Even though advanced HF with atrial fibrilla-
tion is not a class I indication for CRT, many studies reported that 
these patients also benefit from CRT. In a meta-analysis of pro-
spective cohort studies,11) patients in atrial fibrillation had similar 
improvement in LVEF with no significant mortality difference com-
pared to patients with a normal sinus rhythm. In our study, patients 
with atrial fibrillation were effectively stratified into risk groups us-
ing a risk model. The high-risk group demonstrated a 32-fold higher 
mortality than the low-risk group. 
Second, as it was a retrospective design study, our results are 
dependent on the accuracy of medical records. Therefore the accu-
racy of our decision about optimal cardiac medication is lacking. Ad-
ditionally, we enrolled patients from tertiary referral hospitals and 
had a relatively small validation cohort, which may not fully repre-
sent the entire spectrum of advanced HF. 
In conclusion, the prognosis of patients suffering from advanced 
HF with low LVEF and a wide QRS interval who were treated with a 
conventional strategy is primarily dependent on prior stroke, heart 
rate, serum Na, and serum creatinine. We developed a risk model 
based on these four factors that predict mortality risk and strati-
fied patients into three levels of risk (low, intermediate, and high) ef-
fectively. This model may be useful to clinicians for predicting the 
patient’s prognosis, and CRT should be actively considered in high-
risk patients. 
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